Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
University of California San Francisco, San Francisco, California, United States
Stanford University, Palo Alto, California, United States
Taipei Veterans General Hospital, Taipei City, Taiwan
China Medical University Hospital, Taichung, Taiwan
Centre de recherche du CHUS, Sherbrooke, Quebec, Canada
Indiana University, Bloomington, Indiana, United States
University of Kentucky, Lexington, Kentucky, United States
Site TR90001, Bursa, Turkey
Site FR33001, Marseille, France
Site KR82001, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Site CN86014, Beijing, China
Site CN86010, Chengdu, China
Site CN86009, Guangzhou, China
Site CN86001, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.